Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

Authors

Ahmad Iftikhar, The University of Arizona
Hamza Hassan, Rochester General Hospital
Nimra Iftikhar, Dow University of Health Sciences
Adeela Mushtaq, University of Pittsburgh Medical Center
Atif Sohail, Rochester General Hospital
Nathaniel Rosko, Cleveland Clinic
Rajshekhar Chakraborty, Cleveland Clinic
Faryal Razzaq, Foundation University Medical College
Sonia Sandeep, Wilson Medical Center
Jason Neil Valent, Cleveland Clinic
Abraham Sebastian Kanate, West Virginia University
Faiz Anwer, Cleveland Clinic

Author ORCID Identifier

https://orcid.org/0000-0002-2358-7057

https://orcid.org/0000-0003-1775-2703

N/A

N/A

N/A

https://orcid.org/0000-0001-9462-8031

N/A

N/A

N/A

N/A

N/A

https://orcid.org/0000-0001-6914-7439

Document Type

Article

Publication Date

2019

College/Unit

School of Medicine

Abstract

Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune responses. We reviewed the literature on non-Food and Drug Administration (FDA) approved monoclonal antibodies (mAbs) to highlight future perspectives. We searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov to include phase I/II clinical trials. Data from 39 studies (1906 patients) were included. Of all the agents, Isatuximab (Isa, anti-CD38) and F50067 (anti-CXCR4) were the only mAbs to produce encouraging results as monotherapy with overall response rates (ORRs) of 66.7% and 32% respectively. Isa showed activity when used in combination with lenalidomide (Len) and dexamethasone (Dex), producing a clinical benefit rate (CBR) of 83%. Additionally, Isa used in combination with pomalidomide (Pom) and Dex resulted in a CBR of 73%. Indatuximab Ravtansine (anti-CD138 antibody-drug conjugate) produced an ORR of 78% and 79% when used in combination with Len-Dex and Pom-Dex, respectively. Conclusions: Combination therapy using mAbs such as indatuximab, pembrolizumab, lorvotuzumab, siltuximab or dacetuzumab with chemotherapy agents produced better outcomes as compared to monotherapies. Further clinical trials investigating mAbs targeting CD38 used in combination therapy are warranted.

Digital Commons Citation

Iftikhar, Ahmad; Hassan, Hamza; Iftikhar, Nimra; Mushtaq, Adeela; Sohail, Atif; Rosko, Nathaniel; Chakraborty, Rajshekhar; Razzaq, Faryal; Sandeep, Sonia; Valent, Jason Neil; Kanate, Abraham Sebastian; and Anwer, Faiz, "Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development" (2019). Faculty & Staff Scholarship. 2049.
https://researchrepository.wvu.edu/faculty_publications/2049

Source Citation

Iftikhar, A., Hassan, H., Iftikhar, N., Mushtaq, A., Sohail, A., Rosko, N., Chakraborty, R., Razzaq, F., Sandeep, S., Valent, J. N., Kanate, A. S., & Anwer, F. (2019). Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies, 8(2), 34. https://doi.org/10.3390/antib8020034

Comments

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).